HLA-DQ: Celiac disease vs inflammatory bowel disease

doi:10.3748/wjg.v24.i1.96

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8342)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

639

WORD

425

HTML

4038

Tables (1-2)

201

Sum=5303

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1056

Download

1979

Sum=3035

Jan 7, 2018 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jan 7, 2018; 24(1): 96-103
Published online Jan 7, 2018. doi: 10.3748/wjg.v24.i1.96

Table 1 Phenotypical characteristics of inflammatory bowel disease patients n (%)

	All IBD patients	Crohn’s disease patients	UC patients
Number of patients	457 (100)	250 (55)	207 (45)
Gender (female)	202 (44)	122 (49)	80 (39)
Disease location		L1: 60 (24.0), L2: 30 (12.0), L3: 128 (51.2), L1 + L4: 11 (4.4), L2 + L4: 1 (0.4), L3 + L4: 20 (8.0), perianal: 93 (37.2)	Proctitis: 19 (9.2), left colitis: 60 (29.0), extensive colitis: 128 (61.8)
Disease behavior		B1: 88 (35.2), B2: 102 (40.8), B3: 60 (24.0)
Complications	54 (12)	46 (19.7)	8 (4.1)
Extraintestinal manifestations	163 (35.7)	100 (41.8)	63 (31.7)
Surgery¹	166 (37.5)	146 (59.3)	20 (10.2)

¹IBD related surgery: Intestinal or perianal; L1: Distal ileum; L2: Colonic; L3: Ileocolonic; L4: Upper disease; B1: Inflammatory (nonstricturing/nonpenetrating); B2: Stenotic/stricturing and B3: Penetrating/fistulizing.

Table 2 HLA-CeD, -DQ2.5 and -DQ8 for all inflammatory bowel disease patients, ulcerative colitis patients, and Crohn’s disease patients, compared with controls

HLA	Controls (n = 577)	IBD (n = 457)	Crohn’s disease (n = 250)	Ulcerative colitis (n = 207)
HLA-CeD	227, 39.34% (95%CI: 35.36%-43.33%)	156, 34.14% (95%CI: 29.78%-38.48%), P = 0.0852	90, 36% (95%CI: 30.05%-41.95%), P = 0.364	66, 31.88% (95%CI: 25.54%-38.23%), P = 0.0571, PF = 11%
HLA-DQ2.5	137, 23.74% (95%CI: 20.27%-27.22%)	99, 21.66% (95%CI: 17.89%-25.44%), P = 0.381	65, 26.0% (95%CI: 20.6%-31.4%), P = 0.4879	34, 16.43% (95%CI: 11.38%-21.47%), P = 0.0287, PF = 8%
HLA-DQ8	101, 17.50% (95%CI: 14.40%-20.60%)	60, 13.13% (95%CI: 10.03%-16.23%), P = 0.054, PF = 5%	28, 11.20% (95%CI: 7.29%-15.11%), P = 0.0217, PF = 7%	32, 15.46% (95%CI: 10.53%-20.38%), P = 0.501
HLA-DQ2.2	131, 22.70% (95%CI: 19.29%-26.12%)	134, 29.32% (95%CI: 25.15%-33.50%), P = 0.022, EF = 9%	85, 34% (95%CI: 28.13%-39.88%), P = 0.001, EF = 15%	49, 23.67% (95%CI: 17.88%-29.46%), P = 0.856

HLA: Human leucocyte antigen; PF: Preventive fraction.

Citation: Bosca-Watts MM, Minguez M, Planelles D, Navarro S, Rodriguez A, Santiago J, Tosca J, Mora F. HLA-DQ: Celiac disease vs inflammatory bowel disease. World J Gastroenterol 2018; 24(1): 96-103
URL: https://www.wjgnet.com/1007-9327/full/v24/i1/96.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i1.96